HANXBIO-B Buys Back 43,000 H Shares; Treasury Stock Rises to 149,100 Shares

Bulletin Express04-13

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (abbreviation: HANXBIO-B) disclosed a share repurchase on 13 April 2026 under its existing mandate.

The company acquired 43,000 H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 29.18 to HKD 30.70, spending a total of HKD 1.29 million. The transaction represents 0.032 % of HANXBIO-B’s issued share capital (excluding treasury shares) as of the previous disclosure date (10 April 2026).

Following the buyback, the number of issued shares outstanding (excluding treasury shares) fell to 136.07 million, while treasury shares increased to 149,100. The total issued share count remains unchanged at 136.22 million.

The repurchase forms part of the mandate approved on 12 February 2026, which authorises HANXBIO-B to buy back up to 13.62 million shares. Cumulative repurchases under this mandate now total 149,100 shares, equivalent to 0.11 % of the company’s issued share base on the mandate date. In line with Hong Kong listing rules, the company is restricted from issuing, selling or transferring shares until 13 May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1187694663?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-13 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187694663","market":"us","top_or_hot":-1,"title":"HANXBIO-B Buys Back 43,000 H Shares; Treasury Stock Rises to 149,100 Shares","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (abbreviation: HANXBIO-B) disclosed a share repurchase on 13 April 2026 under its existing mandate.</p>\n<p>The company acquired 43,000 H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 29.18 to HKD 30.70, spending a total of HKD 1.29 million. The transaction represents 0.032 % of HANXBIO-B’s issued share capital (excluding treasury shares) as of the previous disclosure date (10 April 2026).</p>\n<p>Following the buyback, the number of issued shares outstanding (excluding treasury shares) fell to 136.07 million, while treasury shares increased to 149,100. The total issued share count remains unchanged at 136.22 million.</p>\n<p>The repurchase forms part of the mandate approved on 12 February 2026, which authorises HANXBIO-B to buy back up to 13.62 million shares. Cumulative repurchases under this mandate now total 149,100 shares, equivalent to 0.11 % of the company’s issued share base on the mandate date. In line with Hong Kong listing rules, the company is restricted from issuing, selling or transferring shares until 13 May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANXBIO-B Buys Back 43,000 H Shares; Treasury Stock Rises to 149,100 Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANXBIO-B Buys Back 43,000 H Shares; Treasury Stock Rises to 149,100 Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-13 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (abbreviation: HANXBIO-B) disclosed a share repurchase on 13 April 2026 under its existing mandate.</p>\n<p>The company acquired 43,000 H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 29.18 to HKD 30.70, spending a total of HKD 1.29 million. The transaction represents 0.032 % of HANXBIO-B’s issued share capital (excluding treasury shares) as of the previous disclosure date (10 April 2026).</p>\n<p>Following the buyback, the number of issued shares outstanding (excluding treasury shares) fell to 136.07 million, while treasury shares increased to 149,100. The total issued share count remains unchanged at 136.22 million.</p>\n<p>The repurchase forms part of the mandate approved on 12 February 2026, which authorises HANXBIO-B to buy back up to 13.62 million shares. Cumulative repurchases under this mandate now total 149,100 shares, equivalent to 0.11 % of the company’s issued share base on the mandate date. In line with Hong Kong listing rules, the company is restricted from issuing, selling or transferring shares until 13 May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1187694663","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187694663","pubTimestamp":1776085351,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (abbreviation: HANXBIO-B) disclosed a share repurchase on 13 April 2026 under its existing mandate. The company acquired 43,000 H-shares on the Hong Kong...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"瀚讯生物-B回购4.3万股H股；库存股增至149,100股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (abbreviation: HANXBIO-B) disclosed a share repurchase on 13 April 2026 under its existing mandate.\nThe company acquired 43,000 H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 29.18 to HKD 30.70, spending a total of HKD 1.29 million. The transaction represents 0.032 % of HANXBIO-B’s issued share capital (excluding treasury shares) as of the previous disclosure date (10 April 2026).\nFollowing the buyback, the number of issued shares outstanding (excluding treasury shares) fell to 136.07 million, while treasury shares increased to 149,100. The total issued share count remains unchanged at 136.22 million.\nThe repurchase forms part of the mandate approved on 12 February 2026, which authorises HANXBIO-B to buy back up to 13.62 million shares. Cumulative repurchases under this mandate now total 149,100 shares, equivalent to 0.11 % of the company’s issued share base on the mandate date. In line with Hong Kong listing rules, the company is restricted from issuing, selling or transferring shares until 13 May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1187694663","isCrawlerRequest":true}